Alkoxybenzo-five-membered (six-membered) heterocyclic amine compound and pharmaceutical use thereof
Alkoxybenzeno five- or six-member heterocyclic amines compounds, their pharmaceutically acceptable salts, and pharmaceutical compositions are used as the active ingredients, and their application in drugs which can prevent and cure diseases caused by abnormal increasing of SM. These diseases caused by abnormal increasing of SM include atherosclerosis, type II diabetes, fatty liver, obesity, metabolic syndromes, enteritis and other inflammatory diseases.
1. Benzeno five member heterocyclic amine compounds represented by formula (I), and their pharmaceutically acceptable salts, wherein formula (I) is
wherein,
X and Y are independently selected from oxygen, nitrogen, and sulfur; and X and Y are not both oxygen or sulfur;
R 1 is chosen from benzene ring or 5-6 membered heterocycle, wherein the heteroatoms in the heterocycle are one to three atoms optionally selected from oxygen, nitrogen and sulfur;
R 2 is chosen from one of hydrogen, methyl, ethyl, and propyl;
R 3 is chosen from phenyl methylene and substituted phenyl methylene, wherein the substituents in phenyl are one to three groups independently selected from halogen, —CN, C 1 -C 3 alkyl, C 1 -C 3 alkoxyl, C 1 -C 3 haloalkyl, C 1 -C 3 haloalkoxyl, wherein each of haloalkyl or haloalkoxyl independently contains one to three halogen atoms, the halogen atom is selected from F, Cl and Br, wherein the compounds comprise the following structures:
2. The heterocyclic amine compounds according to claim 1 , further comprises the following structures:
3. The heterocyclic amine compounds according to claim 1 , wherein the pharmaceutically acceptable salts comprise hydrochloride salts, hydrogen bromide salts, tartrate and methanesulfonate.
4. A pharmaceutical composition with medicinally acceptable carriers comprising the heterocyclic amine compounds and their pharmaceutically acceptable salts according to claim 1 .
5. A method of treatment of abnormal increase of sphingomyelin level, comprising treating a patient of said disease with the pharmaceutical composition with medicinally acceptable carriers, the heterocyclic amine compounds and their pharmaceutically acceptable salts according to claim 1 .
6. The heterocyclic amine compounds according to claim 1 , wherein the pharmaceutically acceptable salts comprise solvates of the heterocyclic amine compounds, wherein the solvates comprise water, ethanol, and methanol.
7. A method of treatment of diseases caused by abnormal increase of sphingomyelin level, comprising treating a patient of said diseases with drugs prepared from the pharmaceutical composition with medicinally acceptable carriers, the heterocyclic amine compounds and their pharmaceutically acceptable salts according to claim 5 .
8. The method according to claim 7 , wherein the diseases are selected from atherosclerosis, type II diabetes, fatty liver, obesity, metabolic syndromes, enteritis and other inflammatory diseases.
9. The heterocyclic amine compounds according to claim 1 , wherein the compounds comprise the following structures:
wherein X, Y, R 2 and R 3 are defined as above in claim 1 .
10. The pharmaceutical composition with medicinally acceptable carriers comprising the heterocyclic amine compounds and their pharmaceutically acceptable salts according to claim 4 , wherein the pharmaceutically acceptable salts comprise solvates of the heterocyclic amine compounds, wherein the solvates comprise water, ethanol, and methanol.